What is Arvinas?
Founded in 2013 and headquartered in New Haven, Connecticut, Arvinas is at the forefront of a new therapeutic modality aimed at degrading disease-causing proteins. The company's innovative approach targets the root cause of various severe illnesses, positioning it as a key player in the biopharmaceutical innovation landscape. Its clinical-stage development signifies a transition from early research to tangible therapeutic solutions, with a focus on improving patient outcomes through advanced protein degradation technology.
How much funding has Arvinas raised?
Arvinas has raised a total of $234.8M across 5 funding rounds:
Corporate Investment
$3.3M
Series A
$15M
Series B
$41.6M
Series C
$55M
Stock Offering
$120M
Corporate Investment (2013): $3.3M with participation from Connecticut Department of Economic and Community Development and Connecticut Innovations
Series A (2013): $15M led by Connecticut Innovations, Elm Street Ventures, Canaan Partners, and 5AM Ventures
Series B (2015): $41.6M supported by New Leaf Venture Partners, Canaan Partners, 5AM Ventures, OrbiMed, and RA Capital Management
Series C (2018): $55M featuring New Leaf Venture Partners, 5AM Ventures, Deerfield, Sirona Capital, RA Capital Management, Canaan Partners, Nextech Invest, Hillhouse Capital, and OrbiMed
Stock Issuance/Offering (2018): $120M backed by Undisclosed
Key Investors in Arvinas
New Leaf Venture Partners
New Leaf Venture Partners (www.nlvpartners.com) is a venture capital firm specializing in early-stage investments within the life sciences sector, focusing on companies developing innovative therapeutics and technologies.
5AM Ventures
5AM Ventures is a life science focused venture capital firm that backs early stage biotech and health care innovators, partnering closely with founders to shape companies, fund rigorous science and help bring new therapies and technologies to patients.
Deerfield
Deerfield Management is an investment firm focused on advancing healthcare through investment, intelligence, and philanthropy, supporting companies across the healthcare ecosystem with flexible funding models and driving innovation.
What's next for Arvinas?
The substantial enterprise-level funding and recent strategic investment indicate Arvinas is poised for accelerated growth and pipeline expansion. This capital infusion is expected to fuel further clinical trials, enhance manufacturing capabilities, and potentially support commercialization efforts for its lead drug candidates. The company's trajectory suggests a strong focus on advancing its protein degradation platform to address unmet medical needs across a spectrum of serious conditions, solidifying its position in the competitive biotech sector.
See full Arvinas company page
